Menu

Blog

Nov 1, 2023

Docetaxel use associated with significant reduction in prostate cancer death in very poor prognostic group

Posted by in category: biotech/medical

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis. The question remains as to whether the chemotherapy drug docetaxel, which increases survival in metastatic prostate cancer, can improve the cure rate in these patients.

In a new study by investigators from Brigham and Women’s Hospital, a meta-analysis of five prospective randomized (RCTs) found that adding docetaxel to standard-of-care (SOC) treatment was associated with a 70% reduction in death from prostate cancer-specific mortality (PCSM). The study was published today in JAMA Network Open.

Investigators performed a of the RCTs evaluating SOC treatment with radiotherapy and androgen deprivation therapy or with versus SOC plus docetaxel. The final study cohort of 2,184 patients included 145 eligible patients (6.6%) across four eligible RCTs.

Comments are closed.